LONDON and NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that at the Annual General Meeting of the Company held at 10.00 a.m. on 16 July 2020, all of the resolutions were duly passed.
The results of the proxy voting will be available shortly on the Company’s website, www.tizianalifesciences.com.The person who arranged for the release of this announcement was Keeren Shah, Group Financial Controller.About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to milciclib, the Company is also developing foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody known to the company in clinical development in the world. This compound has potential application in a wide range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.The information contained in this announcement is inside information for the purposes of article 7 of regulation 596/2014For further enquiries: 


Bay Street News